{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=83", "query": { "intervention": "Blinded (placebo)", "page": 83 }, "page_size": 10 }, "pagination": { "page": 83, "page_size": 10, "total_count": 2216, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=84&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=82&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T10:24:29.534Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02702388", "title": "A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2017-06-08", "completion_date": "2020-09-10", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 16, "location_summary": "La Jolla, California • San Diego, California • Torrance, California + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702388" }, { "nct_id": "NCT00861029", "title": "VEG111485: A QTc Study of Pazopanib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Placebo for pazopanib", "type": "OTHER" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo for moxifloxacin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2009-03-19", "completion_date": "2010-02-15", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 8, "location_summary": "Duarte, California • Santa Monica, California • Detroit, Michigan + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861029" }, { "nct_id": "NCT04644185", "title": "The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "SCTA01", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sinocelltech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2021-03-27", "completion_date": "2022-02-11", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 1, "location_summary": "Somers Point, New Jersey", "locations": [ { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644185" }, { "nct_id": "NCT04693715", "title": "Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stroke, Ischemic" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2021-07-07", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 7, "location_summary": "Chicago, Illinois • Portland, Oregon • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04693715" }, { "nct_id": "NCT01328951", "title": "A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Second-Line Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 643, "start_date": "2011-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 9, "location_summary": "Gilroy, California • Washington D.C., District of Columbia • Kansas City, Missouri + 6 more", "locations": [ { "city": "Gilroy", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Missoula", "state": "Montana" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328951" }, { "nct_id": "NCT06008756", "title": "Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arteriosclerosis", "Hypercholesterolaemia" ], "interventions": [ { "name": "Enlicitide Decanoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14550, "start_date": "2023-10-09", "completion_date": "2031-11-29", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 132, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008756" }, { "nct_id": "NCT02620631", "title": "Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Pain" ], "interventions": [ { "name": "Morphine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 54, "start_date": "2011-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02620631" }, { "nct_id": "NCT02696031", "title": "Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-radiographic Spondyloarthritis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 555, "start_date": "2016-04-29", "completion_date": "2021-03-11", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02696031" }, { "nct_id": "NCT02100696", "title": "A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrozulimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 609, "start_date": "2014-05-21", "completion_date": "2020-04-16", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 38, "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100696" }, { "nct_id": "NCT03134183", "title": "24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abortion, Second Trimester" ], "interventions": [ { "name": "Vaginal Misoprostol", "type": "DRUG" }, { "name": "Buccal Misoprostol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 70, "start_date": "2016-11-19", "completion_date": "2017-08-01", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-11-01T10:24:29.534Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03134183" } ] }